XML 22 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenues:    
Total revenues $ 199,614,000 $ 130,193,000
Cost of sales (49,245,000) (39,640,000)
Gross profit 150,369,000 90,553,000
Operating expenses:    
Selling, general and administrative 129,064,000 83,090,000
Research and development 12,230,000 6,652,000
Impairment of long-lived assets 253,000 380,000
Total operating expenses 141,547,000 90,122,000
Income from operations 8,822,000 431,000
Other (expense) income:    
Interest expense, net (22,786,000) (21,324,000)
Investment (loss) gain from Eton Pharmaceuticals (3,171,000) 3,092,000
Loss on extinguishment of debt (5,465,000)
Other expense, net (185,000) (444,000)
Total other expense, net (26,142,000) (24,141,000)
Loss before income taxes (17,320,000) (23,710,000)
Income tax expense (161,000) (701,000)
Net loss $ (17,481,000) $ (24,411,000)
Basic net loss per share of common stock $ (0.49) $ (0.75)
Diluted net loss per share of common stock $ (0.49) $ (0.75)
Weighted average number of shares of common stock outstanding, basic 35,650,714 32,616,777
Weighted average number of shares of common stock outstanding, diluted 35,650,714 32,616,777
Product Sales Net [Member]    
Revenues:    
Total revenues $ 198,619,000 $ 117,447,000
Other Revenues [Member]    
Revenues:    
Total revenues $ 995,000 $ 12,746,000